Share-based Payment Arrangement, Expense of Oncternal Therapeutics, Inc. from 31 Dec 2010 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Oncternal Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2024.
  • Oncternal Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $1,854,000, a 8% increase year-over-year.
  • Oncternal Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $6,814,000, a 3.8% decline year-over-year.
  • Oncternal Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,500,000, a 0.93% increase from 2022.
  • Oncternal Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,431,000, a 26% increase from 2021.
  • Oncternal Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $5,875,000, a 278% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Oncternal Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $6,814,000 $1,854,000 +$137,000 +8% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2024 2024 Q3
Q2 2024 $6,677,000 $1,382,000 -$298,000 -18% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $6,975,000 $1,360,000 -$525,000 -28% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $7,500,000 $2,218,000 +$416,000 +23% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
Q3 2023 $7,084,000 $1,717,000 -$257,000 -13% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $7,341,000 $1,680,000 +$3,000 +0.18% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $7,338,000 $1,885,000 -$93,000 -4.7% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $7,431,000 $1,802,000 +$89,000 +5.2% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 $7,342,000 $1,974,000 +$486,000 +33% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $6,856,000 $1,677,000 -$159,000 -8.7% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $7,015,000 $1,978,000 +$1,140,000 +136% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $5,875,000 $1,713,000 +$1,306,000 +321% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $4,569,000 $1,488,000 +$1,081,000 +266% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $3,488,000 $1,836,000 +$1,493,000 +435% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $1,995,000 $838,000 +$439,000 +110% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $1,556,000 $407,000 +$92,000 +29% 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $1,464,000 $407,000 +$317,000 +352% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $1,147,000 $343,000 +$280,000 +444% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $867,000 $399,000 +$360,000 +923% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $507,000 $315,000 +$906,000 01 Oct 2019 31 Dec 2019 10-K/A 12 Mar 2021 2020 FY
Q3 2019 $399,000 $90,000 +$48,000 +114% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $447,000 $63,000 +$22,000 +54% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $469,000 $39,000 -$649,000 -94% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $180,000 $591,000 -$1,559,000 -161% 01 Oct 2018 31 Dec 2018 10-K 16 Mar 2020 2019 FY
Q3 2018 $1,739,000 $42,000 -$902,000 -96% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $2,641,000 $41,000 -$660,000 -94% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q1 2018 $3,301,000 $688,000 -$16,000 -2.3% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q4 2017 $3,317,000 $968,000 +$289,000 +43% 01 Oct 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
Q3 2017 $3,028,000 $944,000 +$92,000 +11% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $2,936,000 $701,000 -$113,000 -14% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 $3,049,000 $704,000 -$40,000 -5.4% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018 2018 Q1
Q4 2016 $3,089,000 $679,000 -$101,000 -13% 01 Oct 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
Q3 2016 $3,190,000 $852,000 +$98,000 +13% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017 2017 Q3
Q2 2016 $3,092,000 $814,000 +$65,000 +8.7% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2017 Q2
Q1 2016 $3,027,000 $744,000 +$294,000 +65% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1
Q4 2015 $2,733,000 $780,000 +$507,000 +186% 01 Oct 2015 31 Dec 2015 10-K 13 Mar 2018 2017 FY
Q3 2015 $2,226,000 $754,000 +$488,000 +183% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $1,738,000 $749,000 -$1,018,000 -58% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $2,756,000 $450,000 -$1,797,000 -80% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $4,553,000 $273,000 -$1,263,000 -82% 01 Oct 2014 31 Dec 2014 10-K 24 Mar 2017 2016 FY
Q3 2014 $5,816,000 $266,000 -$496,000 -65% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $6,312,000 $1,767,000 +$1,053,000 +147% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q2
Q1 2014 $5,259,000 $2,247,000 +$1,391,000 +162% 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1
Q4 2013 $3,868,000 $1,536,000 +$725,000 +89% 01 Oct 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
Q3 2013 $3,143,000 $762,000 -$31,000 -3.9% 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014 2014 Q3
Q2 2013 $3,174,000 $714,000 +$428,000 +150% 01 Apr 2013 30 Jun 2013 10-Q 05 Aug 2014 2014 Q2
Q1 2013 $2,746,000 $856,000 -$71,000 -7.7% 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
Q4 2012 $2,817,000 $811,000 01 Oct 2012 31 Dec 2012 10-K 16 Mar 2015 2014 FY
Q3 2012 $793,000 -$333,000 -30% 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013 2013 Q3
Q2 2012 $286,000 -$657,000 -70% 01 Apr 2012 30 Jun 2012 10-Q 22 Jul 2013 2013 Q2
Q1 2012 $927,000 01 Jan 2012 31 Mar 2012 10-Q 06 May 2013 2013 Q1
Q3 2011 $1,126,000 01 Jul 2011 30 Sep 2011 10-Q 08 Nov 2012 2012 Q3
Q2 2011 $943,000 01 Apr 2011 30 Jun 2011 10-Q 08 Aug 2012 2012 Q2

Oncternal Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $7,500,000 +$69,000 +0.93% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
2022 $7,431,000 +$1,556,000 +26% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $5,875,000 +$4,319,000 +278% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $1,556,000 +$1,049,000 +207% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $507,000 +$327,000 +182% 01 Jan 2019 31 Dec 2019 10-K/A 12 Mar 2021 2020 FY
2018 $180,000 -$3,137,000 -95% 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2020 2019 FY
2017 $3,317,000 +$228,000 +7.4% 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
2016 $3,089,000 +$356,000 +13% 01 Jan 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
2015 $2,733,000 -$1,820,000 -40% 01 Jan 2015 31 Dec 2015 10-K 13 Mar 2018 2017 FY
2014 $4,553,000 +$685,000 +18% 01 Jan 2014 31 Dec 2014 10-K 24 Mar 2017 2016 FY
2013 $3,868,000 +$1,051,000 +37% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
2012 $2,817,000 -$1,587,000 -36% 01 Jan 2012 31 Dec 2012 10-K 16 Mar 2015 2014 FY
2011 $4,404,000 -$482,000 -9.9% 01 Jan 2011 31 Dec 2011 10-K 12 Mar 2014 2013 FY
2010 $4,886,000 01 Jan 2010 31 Dec 2010 10-K 05 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.